Vanguard discloses 6.35% Coeptis Therapeutics (COEP) stake in 13G filing

Rhea-AI Filing Summary

The Vanguard Group has disclosed a significant ownership position in Coeptis Therapeutics Holdings Inc common stock. Vanguard reports beneficial ownership of 339,486 shares, representing 6.35% of the outstanding common stock, with shared voting power over 26,244 shares and shared dispositive power over 339,486 shares.

The Vanguard Total Stock Market Index Fund Investor Shares is separately reported as beneficially owning 268,093 shares, or 5.02% of the class, with sole voting power over those shares. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries will report beneficial ownership on a disaggregated basis. The filing certifies that the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Coeptis.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Coeptis Therapeutics Holdings Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

19207A207

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 19207A207

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 26,244.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 339,486.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

339,486.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.35 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

SCHEDULE 13G

CUSIP No. 19207A207

1

Names of Reporting Persons

Vanguard Total Stock Market Index Fund Investor Shares-23-2671505

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 268,093.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

268,093.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.02 %

12

Type of Reporting Person (See Instructions)

IV

Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. As of that date, The Vanguard Group, Inc. no longer performs portfolio management services or administers proxy voting. In accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. anticipates that certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that currently have, or are deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Coeptis Therapeutics Holdings Inc
(b)	Address of issuer's principal executive offices: 105 Bradford Road, Suite 420, Wexford, PA, 15090
Item 2.
(a)	Name of person filing: The Vanguard Group Vanguard Total Stock Market Index Fund Investor Shares-23-2671505
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 19207A207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 339486
(b)	Percent of class: 6.35 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 26244
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 339486
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Index Funds - Vanguard Total Stock Market Index Fund's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	01/30/2026

Vanguard Total Stock Market Index Fund Investor Shares-23-2671505

Signature:	Ashley Grim
Name/Title:	Treasurer
Date:	01/30/2026

FAQ

What stake does The Vanguard Group report in Coeptis Therapeutics (COEP)?

The Vanguard Group reports beneficial ownership of 339,486 Coeptis shares, representing 6.35% of the common stock. Vanguard has shared voting power over 26,244 shares and shared dispositive power over all 339,486 shares, indicating a sizeable institutional position in the company.

How much Coeptis Therapeutics (COEP) stock does Vanguard Total Stock Market Index Fund hold?

Vanguard Total Stock Market Index Fund Investor Shares reports beneficial ownership of 268,093 Coeptis shares, equal to 5.02% of the common stock. The fund has sole voting power over these shares, reflecting its role as a major indexed institutional holder in Coeptis.

Did Vanguard indicate any intent to influence control of Coeptis Therapeutics (COEP)?

Vanguard certifies the Coeptis shares were acquired and are held in the ordinary course of business, not to change or influence control. The filing states the holdings are not connected with any transaction aimed at controlling Coeptis, other than limited proxy nomination activities referenced by rule.

What internal changes at The Vanguard Group are mentioned in the Coeptis (COEP) filing?

The filing notes that on January 12, 2026, The Vanguard Group, Inc. underwent an internal realignment. After this date, it no longer performs portfolio management or proxy voting, and certain subsidiaries or divisions will report beneficial ownership separately while pursuing the same investment strategies as before.

Who signed the Coeptis Therapeutics (COEP) Schedule 13G on behalf of Vanguard?

The Schedule 13G was signed twice by Ashley Grim, once as Head of Global Fund Administration and once as Treasurer, each dated January 30, 2026. The signatures certify that the information and ownership details reported are true, complete, and correct.

What percentage threshold does Vanguard’s Coeptis (COEP) holding exceed?

Both The Vanguard Group and the Vanguard Total Stock Market Index Fund exceed the 5% ownership threshold in Coeptis common stock. Vanguard reports 6.35% beneficial ownership overall, while the index fund reports 5.02%, triggering this institutional ownership disclosure requirement.